Executive Vice President, Chief Commercial Officer · Sarepta Therapeutics, Inc. (SRPT)

Alexander Cumbo

A named executive officer of Sarepta Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$3,115,158

Salary $428,231Stock awards $0

FY2017: $2,317,784

4th of 5 named executive officers at Sarepta Therapeutics by FY2018 total.

5 named officers on file for Sarepta Therapeutics, FY2018

Alexander Cumbo’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • SRPT’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Sarepta Therapeutics’s whole pay program stands against its peers

  • Sarepta Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SRPT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2019 (DEF 14A).

Free

Get Alexander Cumbo’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Alexander Cumbo compensation by year

Sarepta Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Sarepta Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018
Salary$353,558$428,231
Bonus$0$0
Stock awards$636,416$0
Option awards$1,103,231$2,412,445
Non-equity incentive$212,800$261,545
Pension and deferred compensation$0$0
All other$11,779$12,937
Total$2,317,784$3,115,158

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Sarepta Therapeutics, Inc. DEF 14A filed April 26, 2019, accession 0001564590-19-013364, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Sarepta Therapeutics, Inc. filed document, accession 0001564590-19-013364. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2019.

$2.3M
$3.1M
FY17
FY18
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
PSU4,876$532,118—
Option15,469—$32.63
Option2,524—$13.71
Option5,834—$13.71
Option834—$13.90
Option24,167—$34.64
Option70,000—$71.45

Per the Outstanding Equity Awards at Fiscal Year-End table in Sarepta Therapeutics, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Sarepta Therapeutics’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Gilmore O'NeillM.B. Executive Vice President, Chief Scientific Officer$6,449,176
Sandesh MahatmeExecutive Vice President, Chief Financial Officer and Chief Business Officer$4,219,084
David HowtonExecutive Vice President, General Counsel and Corporate Secretary$3,129,375
Alexander Cumbo · this pageExecutive Vice President, Chief Commercial Officer$3,115,158
Douglas IngramPresident and Chief Executive Officer$1,433,872

The full Sarepta Therapeutics compensation record

free company brief

This page is one person within Sarepta Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Sarepta Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Sarepta Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Alexander Cumbo's compensation dossier · One-time report. No refunds.